Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.71 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12013922 | 0.83 | ACHE (1.00) | ACHEHRH3 | |
| SCHEMBL11865007 | 0.83 | ACHE (0.49) | ACHEHRH3SIGMAR1KCNH2 | |
| SCHEMBL9254022 | 0.82 | HRH3 (0.62) | HRH3SIGMAR1KCNH2 | |
| SCHEMBL17117585 | 0.82 | KCNH2 (0.70) | ACHEHRH3SIGMAR1KCNH2 | |
| SCHEMBL791561 | 0.81 | HRH3 (0.61) | HRH3SIGMAR1CHRNA7KCNH2 | |
| SCHEMBL17828187 | 0.80 | SIGMAR1 (0.77) | HRH3SIGMAR1KCNH2 | |
| SCHEMBL12226961 | 0.78 | CYP2A13 (0.70) | SIGMAR1KCNH2 | |
| SCHEMBL152736 | 0.77 | ACHE (1.00) | ACHEHRH3SIGMAR1KCNH2 | |
| SCHEMBL15084359 | 0.77 | ACHE (0.81) | ACHESIGMAR1 | |
| Hydrochloric Acid SCHEMBL16934720 | 0.74 | ACHE (0.43) | ACHESIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| EP-3042900-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | Fujifilm Corporation (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | ACHE 1829/4885HRH3 232/4885SIGMAR1 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.